Is genetic testing required for pemetinib/pemetinib?

Pemigatinib/Pemigatinib is an antineoplastic agent and a potent and selective small molecule inhibitor of fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, and FGFR3). Pemetinib is indicated for the treatment of cholangiocarcinoma (CCA), including previously treated, unresectable locally advanced or metastatic cholangiocarcinoma using FGFR2 genomic abnormalities (e.g., fusions, rearrangements). Designated by the FDA as an orphan drug for the treatment of cholangiocarcinoma.

Treatment with pemetinib often requires genetic testing. Pemetinib is a targeted drug mainly used to treat cancers related to fibroblast growth factor receptor (FGFR) gene mutations. The goal of genetic testing is to determine whether a patient's tumor carries a specific FGFR gene variation, such as an FGFR2 gene fusion or rearrangement. The presence or absence of these genetic variants is closely related to the therapeutic effectiveness of pemetinib. Through genetic testing, it can be determined whether a patient's tumor is sensitive to pemetinib, thus providing doctors with important basis for treatment decisions. If a patient's tumor carries an FGFR gene mutation and meets the indications for treatment with pemetinib, then the use of pemetinib may lead to better treatment results.

Genetic testing is typically done by analyzing tumor tissue or blood samples. Detection methods may include next generation sequencing (NGS), fluorescence in situ hybridization (FISH) and other technologies. Specific testing methods and requirements may vary among different medical institutions and clinical practices. Before performing genetic testing, doctors will evaluate whether the test is necessary based on the patient's clinical symptoms, tumor characteristics, and other relevant factors. The results of genetic testing are of great significance in selecting appropriate treatment options and predicting treatment effects.